Wan Amir-Jeffery Bin Wan Abdul Majid

Group Chief Executive Officer

Date of First Appointment to Duopharma Biotech
21 September 2020

Date of Appointment as the Group Chief Executive Officer
1 October 2025

Date of Appointment as the Chief Executive
1 December 2025*

53

M

* ‘Chief Executive’ means the principal executive officer of the corporation for the time being, by whatever name called, and whether or not he is a director. In relation thereto, Encik Wan Amir-Jeffery took over the role as Chief Executive of Duopharma Biotech Berhad from the former Group Managing Director on 1 December 2025.

Back

Directorships in Other Public Companies and Other Listed Entities:

  • Listed Entities

    • None

  • Non-Listed Public Companies
    • Malaysian Organisation of Pharmaceutical Industries (MOPI)

Family Relationship with Any Director and/or Major Shareholder:

None

Conflict of Interest or Potential Conflict of Interest, Including Interest in Any Competing Business with the Company or Its Subsidiaries:

None

List of Convictions for Offences within the Past 5 Years and Particulars of Any Public Sanction or Penalty Imposed by the Relevant Regulatory Bodies during the Financial Year:

None

Details of Any Interest in the Securities of the Company or Its Subsidiaries:

None

Academic/Professional Qualification/Membership(s):

  • Bachelor of Business Administration – International Trade, University of Central Arkansas, United States of America
  • Senior Management Development Program, Harvard Business School, United States of America
  • Qualified Risk Director (QRD) Program, Institute of Enterprise Risk Practitioners
  • Member of the Institute of Corporate Directors Malaysia (ICDM)
Back

Past Appointments/Experiences:

  • Executive Director, Resources Management (SRM) Sdn Bhd from 1997 to 2007
  • Lead Business Analyst, Biomedical Business Development and Investment Division, Malaysian Biotechnology Corporation (BiotechCorp) Sdn Bhd from 2007 to 2008 Vice President, Biomedical Business Development and Investment Division, Malaysian Biotechnology Corporation (BiotechCorp) Sdn Bhd from 2008 to 2013
  • Chief Executive Officer, Johor Biotechnology & Biodiversity Corporation and J-Biotech Holdings Sdn. Bhd (“J-Biotech”) from 2013 to 2016
  • Chief Strategy Officer, Duopharma Biotech Berhad from 2016 to 2018
  • Chief Operating Officer, Duopharma Biotech Berhad from 2018 to 2020
  • Chief Commercial Officer, Duopharma Biotech Berhad from 2020 to 2022
  • Chief Executive Officer – Commercial, Duopharma Biotech Berhad from 2022 to 2024
  • Chief Executive Officer – Group Operations, Duopharma Biotech Berhad from 2024 to 2025

Other Current Appointment(s):

  • Chairman of Duopharma Biotech’s Group Management Committee
  • Director of the Executive Council of the Malaysian Organisation of Pharmaceutical Industries (MOPI)
  • INTI University Advisory Board Member

Notes:

  • Redesignated to current position on 21 October 2024.

  • Previously served as Chief Executive Officer – Commercial from 2022 to 2024.

Back